Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

NCT03836469 | Completed

• 1 other identifier: LACOG 0118
• Study Type: observational
• Target: 403
• Locations: 1 country
• Sites: 1

Brief Summary

RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in Brazil.

Conditions

Lung Cancer, Non-small Cell

Keywords

Lung cancer; Non-small cell

Outcome Measures

Primary Outcomes (1)

• Overall survival

  defined as time from diagnosis to death of any cause;

  Up to June 30, 2018

Secondary Outcomes (2)

• Progression free survival

  Up to June 30, 2018

• Time to next treatment

  Up to June 30, 2018

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with stage IIIA or IIIB NSCLC in the period of January 2015 to December 2016.

You may qualify if:

• Patients aged 18 years or older;
• Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016;
• Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System;
• Any NSCLC histological subtype and molecular mutation;
• Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
• Patients assigned by treating physician to any therapy or palliative care;
• Access to patient medical chart for data collection.

You may not qualify if:

• Small cell lung cancer and non-invasive NSCLC;
• Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Sponsors & Collaborators

• Latin American Cooperative Oncology Group: lead
• AstraZeneca: collaborator

Study Sites (1)

AC Camargo

São Paulo, São Paulo, Brazil

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Vladmir Cláudio Cordeiro de Lima

  Latin American Cooperative Oncology Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 8, 2019
• First Posted: February 11, 2019
• Study Start: September 25, 2019
• Primary Completion: June 9, 2022
• Study Completion: June 9, 2022
• Last Updated: February 20, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)